CRP and asthma: Therapeutic response appeared to be independent of asthma and EGPA diseases duration, duration of omalizumab OCS use, having vasculitis, CRP levels, sedimentation levels, and eosinophil numbers, but we could not analyze which patient characteristics would predict omalizumab responsiveness due to the small number of patients.